BGA
SRNE

Belmont Global Advisors’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Belmont Global Advisors’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-50,000
Closed -$578K – 120
2015
Q1 		$578K Buy
+50,000
New +$578K 0.59% 44

Other funds holding SRNE

Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Cormorant Asset Management
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock Fund Advisors
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
BlackRock Institutional Trust
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $72.7B AUM 26.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Belmont Global Advisors's SRNE Position: Q2 2015 in Review

Belmont Global Advisors sold out of Sorrento Therapeutics, Inc. (SRNE) in Q2 2015, closing a stake of 50,000 shares — an estimated $578K sold.

Belmont Global Advisors first reported a position in SRNE in Q1 2015 and held it in 1 quarter. The position peaked at $578K in Q1 2015. 75 funds tracked by Wall St. Rank hold SRNE as of Q2 2015.

  • Belmont Global Advisors reported no remaining Sorrento Therapeutics, Inc. position as of Q2 2015 after selling out during the quarter.
  • Belmont Global Advisors sold 50,000 Sorrento Therapeutics, Inc. shares in Q2 2015, an estimated $578K.
  • Belmont Global Advisors first reported a position in Sorrento Therapeutics, Inc. in Q1 2015 and held it in 1 quarter.
  • Belmont Global Advisors's Sorrento Therapeutics, Inc. position peaked at $578K in Q1 2015.
  • 75 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2015.

Based on Belmont Global Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.